Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:busulfan
|
| gptkbp:approvalYear |
1999
|
| gptkbp:ATCCode |
L01AB01
|
| gptkbp:chemicalClass |
antineoplastic agent
|
| gptkbp:contraindication |
hypersensitivity to busulfan
|
| gptkbp:eliminationHalfLife |
2.5 hours
|
| gptkbp:form |
injectable solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Busulfex
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Otsuka_America_Pharmaceutical,_Inc.
|
| gptkbp:mechanismOfAction |
DNA crosslinking
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
pulmonary fibrosis
seizures liver toxicity bone marrow suppression |
| gptkbp:usedFor |
gptkb:chronic_myelogenous_leukemia
conditioning prior to hematopoietic progenitor cell transplantation |
| gptkbp:bfsParent |
gptkb:Otsuka_Holdings
|
| gptkbp:bfsLayer |
6
|